US6444798B1
(en)
*
|
1988-06-06 |
2002-09-03 |
Steven Albert Benner |
Chimeras of sulfur-linked oligonucleotide analogs and DNA and RNA
|
US6783931B1
(en)
|
1990-01-11 |
2004-08-31 |
Isis Pharmaceuticals, Inc. |
Amine-derivatized nucleosides and oligonucleosides
|
US5859221A
(en)
*
|
1990-01-11 |
1999-01-12 |
Isis Pharmaceuticals, Inc. |
2'-modified oligonucleotides
|
US5872232A
(en)
*
|
1990-01-11 |
1999-02-16 |
Isis Pharmaceuticals Inc. |
2'-O-modified oligonucleotides
|
US5681941A
(en)
*
|
1990-01-11 |
1997-10-28 |
Isis Pharmaceuticals, Inc. |
Substituted purines and oligonucleotide cross-linking
|
US20040142899A1
(en)
*
|
1990-01-11 |
2004-07-22 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
|
US6358931B1
(en)
|
1990-01-11 |
2002-03-19 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulating RNA
|
US6753423B1
(en)
|
1990-01-11 |
2004-06-22 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
|
US6005087A
(en)
*
|
1995-06-06 |
1999-12-21 |
Isis Pharmaceuticals, Inc. |
2'-modified oligonucleotides
|
US7037646B1
(en)
|
1990-01-11 |
2006-05-02 |
Isis Pharmaceuticals, Inc. |
Amine-derivatized nucleosides and oligonucleosides
|
US6399754B1
(en)
*
|
1991-12-24 |
2002-06-04 |
Isis Pharmaceuticals, Inc. |
Sugar modified oligonucleotides
|
US6339066B1
(en)
|
1990-01-11 |
2002-01-15 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C
|
US5623070A
(en)
*
|
1990-07-27 |
1997-04-22 |
Isis Pharmaceuticals, Inc. |
Heteroatomic oligonucleoside linkages
|
US5541307A
(en)
*
|
1990-07-27 |
1996-07-30 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogs and solid phase synthesis thereof
|
US5618704A
(en)
*
|
1990-07-27 |
1997-04-08 |
Isis Pharmacueticals, Inc. |
Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
|
US5386023A
(en)
*
|
1990-07-27 |
1995-01-31 |
Isis Pharmaceuticals |
Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
|
US6121433A
(en)
*
|
1990-07-27 |
2000-09-19 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds having nitrogen-containing linkages
|
US5610289A
(en)
*
|
1990-07-27 |
1997-03-11 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogues
|
US5998603A
(en)
*
|
1994-09-29 |
1999-12-07 |
Isis Pharmaceuticals, Inc. |
4'-desmethyl nucleoside analogs, and oligomers thereof
|
US5602240A
(en)
*
|
1990-07-27 |
1997-02-11 |
Ciba Geigy Ag. |
Backbone modified oligonucleotide analogs
|
US5378825A
(en)
*
|
1990-07-27 |
1995-01-03 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogs
|
MY107332A
(en)
*
|
1990-08-03 |
1995-11-30 |
Sterling Drug Inc |
Compounds and methods for inhibiting gene expression.
|
US5789573A
(en)
*
|
1990-08-14 |
1998-08-04 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
|
US5596086A
(en)
*
|
1990-09-20 |
1997-01-21 |
Gilead Sciences, Inc. |
Modified internucleoside linkages having one nitrogen and two carbon atoms
|
US5965722A
(en)
*
|
1991-05-21 |
1999-10-12 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of ras gene with chimeric and alternating oligonucleotides
|
US7015315B1
(en)
|
1991-12-24 |
2006-03-21 |
Isis Pharmaceuticals, Inc. |
Gapped oligonucleotides
|
US6335434B1
(en)
|
1998-06-16 |
2002-01-01 |
Isis Pharmaceuticals, Inc., |
Nucleosidic and non-nucleosidic folate conjugates
|
US8153602B1
(en)
|
1991-11-19 |
2012-04-10 |
Isis Pharmaceuticals, Inc. |
Composition and methods for the pulmonary delivery of nucleic acids
|
US5359044A
(en)
*
|
1991-12-13 |
1994-10-25 |
Isis Pharmaceuticals |
Cyclobutyl oligonucleotide surrogates
|
EP0635023B1
(en)
*
|
1992-03-05 |
2002-02-06 |
Isis Pharmaceuticals, Inc. |
Covalently cross-linked oligonucleotides
|
US5543507A
(en)
*
|
1992-03-05 |
1996-08-06 |
Isis Pharmaceuticals, Inc. |
Covalently cross-linked oligonucleotides
|
US6537973B1
(en)
|
1992-03-16 |
2003-03-25 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide inhibition of protein kinase C
|
US6117847A
(en)
*
|
1992-03-16 |
2000-09-12 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for enhanced modulation of protein kinase C expression
|
GB9207380D0
(en)
*
|
1992-04-03 |
1992-05-13 |
Ici Plc |
Compounds
|
US5434257A
(en)
*
|
1992-06-01 |
1995-07-18 |
Gilead Sciences, Inc. |
Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
|
US5817781A
(en)
*
|
1992-06-01 |
1998-10-06 |
Gilead Sciences, Inc. |
Modified internucleoside linkages (II)
|
DE69334241D1
(de)
*
|
1992-06-24 |
2008-10-09 |
Isis Pharmaceuticals Inc |
Heteroatomische oligonukleosidbindungen
|
US5872242A
(en)
*
|
1992-10-05 |
1999-02-16 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide inhibition of ras
|
KR100199247B1
(ko)
*
|
1992-10-05 |
1999-06-15 |
파샬 비. 린네 |
Ras 유전자의 안티센스 올리고뉴클레오티드 저해
|
US20030013670A1
(en)
*
|
1992-10-05 |
2003-01-16 |
Monia Brett P. |
Antisense oligonucleotide inhibition of ras
|
US6784290B1
(en)
|
1992-10-05 |
2004-08-31 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide inhibition of ras
|
US5985558A
(en)
|
1997-04-14 |
1999-11-16 |
Isis Pharmaceuticals Inc. |
Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos
|
JPH08508491A
(ja)
*
|
1993-03-31 |
1996-09-10 |
スターリング ウインスロップ インコーポレイティド |
ホスホジエステル結合をアミド結合に置き換えたオリゴヌクレオチド
|
JPH08508489A
(ja)
*
|
1993-03-31 |
1996-09-10 |
スターリング ウィンスロップ インコーポレイティド |
二官能価ヌクレオシド、それらのオリゴマーならびにそれらの製造方法及び使用方法
|
GB9311682D0
(en)
*
|
1993-06-05 |
1993-07-21 |
Ciba Geigy Ag |
Chemical compounds
|
US6605708B1
(en)
|
1993-07-28 |
2003-08-12 |
Hybridon, Inc. |
Building blocks with carbamate internucleoside linkages and oligonucleotides derived therefrom
|
DE69433036T2
(de)
|
1993-09-03 |
2004-05-27 |
Isis Pharmaceuticals, Inc., Carlsbad |
Aminoderivatisierte nukleoside und oligonukleoside
|
US6653458B1
(en)
|
1993-09-03 |
2003-11-25 |
Isis Pharmaceuticals, Inc. |
Modified oligonucleotides
|
DK0741741T3
(da)
*
|
1994-01-26 |
2002-12-23 |
Novartis Ag |
Modificerede oligonucleotider
|
US5625050A
(en)
*
|
1994-03-31 |
1997-04-29 |
Amgen Inc. |
Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
|
US6391636B1
(en)
|
1994-05-31 |
2002-05-21 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of raf gene expression
|
US5981731A
(en)
*
|
1994-05-31 |
1999-11-09 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of B-raf gene expression
|
WO1996005298A1
(en)
*
|
1994-08-09 |
1996-02-22 |
Ciba-Geigy Ag |
Antitumor antisense oligonucleotides
|
GB9417746D0
(en)
*
|
1994-09-03 |
1994-10-19 |
Ciba Geigy Ag |
Chemical compounds
|
GB9417938D0
(en)
*
|
1994-09-06 |
1994-10-26 |
Ciba Geigy Ag |
Compounds
|
US5681940A
(en)
*
|
1994-11-02 |
1997-10-28 |
Icn Pharmaceuticals |
Sugar modified nucleosides and oligonucleotides
|
EP0714907A1
(en)
*
|
1994-11-30 |
1996-06-05 |
F. Hoffmann-La Roche Ag |
Oligoribonucleotides with amide backbone
|
US5807718A
(en)
|
1994-12-02 |
1998-09-15 |
The Scripps Research Institute |
Enzymatic DNA molecules
|
US6207826B1
(en)
|
1995-03-27 |
2001-03-27 |
Isis Pharmaceuticals, Inc. |
Macrocyclic compounds having nitrogen-containing linkages
|
US6107482A
(en)
*
|
1995-03-27 |
2000-08-22 |
Isis Pharmaceuticals, Inc. |
Nitrogenous macrocyclic compounds
|
US6420549B1
(en)
*
|
1995-06-06 |
2002-07-16 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide analogs having modified dimers
|
US5665721A
(en)
*
|
1995-06-07 |
1997-09-09 |
Abbott Laboratories |
Heterocyclic substituted cyclopentane compounds
|
US6143749A
(en)
*
|
1995-06-07 |
2000-11-07 |
Abbott Laboratories |
Heterocyclic substituted cyclopentane compounds
|
WO1996040726A1
(en)
|
1995-06-07 |
1996-12-19 |
Genta Incorporated |
Novel carbamate-based cationic lipids
|
US5855911A
(en)
*
|
1995-08-29 |
1999-01-05 |
Board Of Regents, The University Of Texas System |
Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
|
GB9604669D0
(en)
|
1996-03-05 |
1996-05-01 |
Ciba Geigy Ag |
Chemical compounds
|
US5856099A
(en)
*
|
1996-05-21 |
1999-01-05 |
Isis Pharmaceuticals, Inc. |
Antisense compositions and methods for modulating type I interleukin-1 receptor expression
|
US20050042647A1
(en)
*
|
1996-06-06 |
2005-02-24 |
Baker Brenda F. |
Phosphorous-linked oligomeric compounds and their use in gene modulation
|
US20050119470A1
(en)
*
|
1996-06-06 |
2005-06-02 |
Muthiah Manoharan |
Conjugated oligomeric compounds and their use in gene modulation
|
US20040147022A1
(en)
*
|
1996-06-06 |
2004-07-29 |
Baker Brenda F. |
2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
|
US20040161777A1
(en)
*
|
1996-06-06 |
2004-08-19 |
Baker Brenda F. |
Modified oligonucleotides for use in RNA interference
|
US9096636B2
(en)
*
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US5898031A
(en)
*
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
US20040203024A1
(en)
*
|
1996-06-06 |
2004-10-14 |
Baker Brenda F. |
Modified oligonucleotides for use in RNA interference
|
US20040266706A1
(en)
*
|
2002-11-05 |
2004-12-30 |
Muthiah Manoharan |
Cross-linked oligomeric compounds and their use in gene modulation
|
US20070275921A1
(en)
*
|
1996-06-06 |
2007-11-29 |
Isis Pharmaceuticals, Inc. |
Oligomeric Compounds That Facilitate Risc Loading
|
US7812149B2
(en)
*
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
US20050053976A1
(en)
*
|
1996-06-06 |
2005-03-10 |
Baker Brenda F. |
Chimeric oligomeric compounds and their use in gene modulation
|
GB9612600D0
(en)
|
1996-06-13 |
1996-08-21 |
Ciba Geigy Ag |
Chemical compounds
|
AU3340797A
(en)
*
|
1996-06-28 |
1998-01-21 |
Novartis Ag |
Modified oligonucleotides
|
US7309692B1
(en)
*
|
1996-07-08 |
2007-12-18 |
Board Of Regents, The University Of Texas System |
Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1
|
US6077954A
(en)
|
1996-08-01 |
2000-06-20 |
Isis Pharmaceuticals, Inc. |
Substituted heterocyclic compounds
|
US6537783B1
(en)
|
1996-08-02 |
2003-03-25 |
Bio Merieux |
Prefunctionalized nucleotide and process for amplifying a sequence using a prefunctionalized nucleotide
|
US6111085A
(en)
*
|
1996-09-13 |
2000-08-29 |
Isis Pharmaceuticals, Inc. |
Carbamate-derivatized nucleosides and oligonucleosides
|
US6977244B2
(en)
*
|
1996-10-04 |
2005-12-20 |
Board Of Regents, The University Of Texas Systems |
Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
|
US5780241A
(en)
|
1996-11-05 |
1998-07-14 |
Isis Pharmaceuticals, Inc. |
Complex chemical libraries
|
US7235653B2
(en)
|
1996-12-31 |
2007-06-26 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
|
US6077833A
(en)
*
|
1996-12-31 |
2000-06-20 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
|
US6319906B1
(en)
|
1996-12-31 |
2001-11-20 |
Isis Pharmaceuticals |
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
|
US6172209B1
(en)
*
|
1997-02-14 |
2001-01-09 |
Isis Pharmaceuticals Inc. |
Aminooxy-modified oligonucleotides and methods for making same
|
US6127533A
(en)
|
1997-02-14 |
2000-10-03 |
Isis Pharmaceuticals, Inc. |
2'-O-aminooxy-modified oligonucleotides
|
US6639062B2
(en)
*
|
1997-02-14 |
2003-10-28 |
Isis Pharmaceuticals, Inc. |
Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom
|
US6576752B1
(en)
*
|
1997-02-14 |
2003-06-10 |
Isis Pharmaceuticals, Inc. |
Aminooxy functionalized oligomers
|
BRPI9809433B1
(pt)
|
1997-04-29 |
2015-09-08 |
Scripps Research Inst |
moléculas de dna enzimáticas
|
CA2294988C
(en)
|
1997-07-01 |
2015-11-24 |
Isis Pharmaceuticals Inc. |
Compositions and methods for the delivery of oligonucleotides via the alimentary canal
|
US5877309A
(en)
|
1997-08-13 |
1999-03-02 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotides against JNK
|
US6809193B2
(en)
|
1997-08-13 |
2004-10-26 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
|
US20070149472A1
(en)
*
|
1997-08-13 |
2007-06-28 |
Mckay Robert |
Antisense oligonucleotide compositions and methods for the modulation of jnk proteins
|
US6133246A
(en)
*
|
1997-08-13 |
2000-10-17 |
Isis Pharmaceuticals Inc. |
Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
|
US6518017B1
(en)
*
|
1997-10-02 |
2003-02-11 |
Oasis Biosciences Incorporated |
Combinatorial antisense library
|
US20030165888A1
(en)
*
|
2001-07-18 |
2003-09-04 |
Brown Bob D. |
Oligonucleotide probes and primers comprising universal bases for diagnostic purposes
|
US7285288B1
(en)
|
1997-10-03 |
2007-10-23 |
Board Of Regents, The University Of Texas System |
Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
|
US7704962B1
(en)
|
1997-10-03 |
2010-04-27 |
Board Of Regents, The University Of Texas System |
Small oligonucleotides with anti-tumor activity
|
US6232463B1
(en)
|
1997-10-09 |
2001-05-15 |
Isis Pharmaceuticals, Inc. |
Substituted purines and oligonucleotide cross-linking
|
US5948902A
(en)
|
1997-11-20 |
1999-09-07 |
South Alabama Medical Science Foundation |
Antisense oligonucleotides to human serine/threonine protein phosphatase genes
|
US5968748A
(en)
*
|
1998-03-26 |
1999-10-19 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of human HER-2 expression
|
US7321828B2
(en)
|
1998-04-13 |
2008-01-22 |
Isis Pharmaceuticals, Inc. |
System of components for preparing oligonucleotides
|
US20040186071A1
(en)
*
|
1998-04-13 |
2004-09-23 |
Bennett C. Frank |
Antisense modulation of CD40 expression
|
JP2002515514A
(ja)
*
|
1998-05-21 |
2002-05-28 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
オリゴヌクレオチドの局所送逹のための組成物及び方法
|
CA2329130A1
(en)
*
|
1998-05-21 |
1999-11-25 |
Isis Pharmaceuticals Inc. |
Compositions and methods for non-parenteral delivery of oligonucleotides
|
US6300319B1
(en)
|
1998-06-16 |
2001-10-09 |
Isis Pharmaceuticals, Inc. |
Targeted oligonucleotide conjugates
|
US6867294B1
(en)
|
1998-07-14 |
2005-03-15 |
Isis Pharmaceuticals, Inc. |
Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
|
US6673912B1
(en)
|
1998-08-07 |
2004-01-06 |
Isis Pharmaceuticals, Inc. |
2′-O-aminoethyloxyethyl-modified oligonucleotides
|
US6043352A
(en)
|
1998-08-07 |
2000-03-28 |
Isis Pharmaceuticals, Inc. |
2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides
|
US20040009938A1
(en)
*
|
1998-08-07 |
2004-01-15 |
Muthiah Manoharan |
Methods of enhancing renal uptake of oligonucleotides
|
US6175004B1
(en)
|
1998-09-01 |
2001-01-16 |
Isis Pharmaceuticals, Inc. |
Process for the synthesis of oligonucleotides incorporating 2-aminoadenosine
|
US6077709A
(en)
|
1998-09-29 |
2000-06-20 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Survivin expression
|
US6069243A
(en)
*
|
1998-10-06 |
2000-05-30 |
Isis Pharmaceuticals, Inc. |
Process for oligonucleotide synthesis
|
US6667176B1
(en)
|
2000-01-11 |
2003-12-23 |
Geron Corporation |
cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
|
US6492111B1
(en)
|
1998-11-25 |
2002-12-10 |
Isis Pharmaceuticals, Inc. |
In situ binary synthesis of biologically effective molecules
|
US20030180789A1
(en)
*
|
1998-12-30 |
2003-09-25 |
Dale Roderic M.K. |
Arrays with modified oligonucleotide and polynucleotide compositions
|
US6087112A
(en)
*
|
1998-12-30 |
2000-07-11 |
Oligos Etc. Inc. |
Arrays with modified oligonucleotide and polynucleotide compositions
|
US6403779B1
(en)
|
1999-01-08 |
2002-06-11 |
Isis Pharmaceuticals, Inc. |
Regioselective synthesis of 2′-O-modified nucleosides
|
US6399765B1
(en)
|
1999-03-17 |
2002-06-04 |
Isis Pharmaceuticals, Inc. |
Methods for removing dimethoxytrityl groups from oligonucleotides
|
PT1163333E
(pt)
|
1999-03-18 |
2008-02-19 |
Queen Mary & Westfield College |
''inibidores da síntese de endotelina-1''
|
US6235891B1
(en)
|
1999-03-31 |
2001-05-22 |
South Alabama Medical Science Foundation |
Glucocorticoid receptor agonist and decreased PP5
|
US7098192B2
(en)
|
1999-04-08 |
2006-08-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of STAT3 expression
|
CA2365984A1
(en)
*
|
1999-04-08 |
2000-10-19 |
Oasis Biosciences, Inc. |
Antisense oligonucleotides comprising universal and/or degenerate bases
|
US6656730B1
(en)
|
1999-06-15 |
2003-12-02 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides conjugated to protein-binding drugs
|
US6147200A
(en)
*
|
1999-08-19 |
2000-11-14 |
Isis Pharmaceuticals, Inc. |
2'-O-acetamido modified monomers and oligomers
|
US6277982B1
(en)
|
1999-08-20 |
2001-08-21 |
Isis Pharmaceuticals, Inc. |
Alkylation of alcohols, amines, thiols and their derivatives by cyclic sulfate intermediates
|
US6261840B1
(en)
|
2000-01-18 |
2001-07-17 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
US20020055479A1
(en)
|
2000-01-18 |
2002-05-09 |
Cowsert Lex M. |
Antisense modulation of PTP1B expression
|
US7105962B2
(en)
*
|
2000-08-03 |
2006-09-12 |
Matsushita Electric Industrial Co., Ltd. |
Brushless motor for partable electronic equipment with wire treatment technique of coils
|
US7767802B2
(en)
|
2001-01-09 |
2010-08-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
EP2221376B1
(en)
|
2001-06-21 |
2012-11-21 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of superoxide dismutase 1, soluble expression
|
US6964950B2
(en)
|
2001-07-25 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of C-reactive protein expression
|
US7425545B2
(en)
|
2001-07-25 |
2008-09-16 |
Isis Pharmaceuticals, Inc. |
Modulation of C-reactive protein expression
|
US20030096772A1
(en)
|
2001-07-30 |
2003-05-22 |
Crooke Rosanne M. |
Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
|
US7407943B2
(en)
|
2001-08-01 |
2008-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein B expression
|
US7227014B2
(en)
|
2001-08-07 |
2007-06-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein (a) expression
|
US6750019B2
(en)
|
2001-10-09 |
2004-06-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
US6872704B2
(en)
|
2001-10-09 |
2005-03-29 |
Genentech, Inc. |
Acidic mammalian proteins and polynucleotides encoding the same
|
NZ566396A
(en)
|
2001-10-09 |
2009-07-31 |
Isis Pharmaceuticals Inc |
Antisense modulation of insulin-like growth factor binding protein 5 expressions
|
DE10159904A1
(de)
*
|
2001-12-06 |
2003-07-03 |
Adnagen Ag |
Oligonukleotidanordnung, Verfahren zum Nukleotidnachweis sowie Vorrichtung hierfür
|
US6965025B2
(en)
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
US20040043950A1
(en)
*
|
2002-01-03 |
2004-03-04 |
Board Of Regents, The University Of Texas System |
WT1 antisense oligos for the inhibition of breast cancer
|
US20030166282A1
(en)
*
|
2002-02-01 |
2003-09-04 |
David Brown |
High potency siRNAS for reducing the expression of target genes
|
ATE529512T1
(de)
|
2002-02-01 |
2011-11-15 |
Life Technologies Corp |
Doppelsträngige oligonukleotide
|
US20060009409A1
(en)
|
2002-02-01 |
2006-01-12 |
Woolf Tod M |
Double-stranded oligonucleotides
|
US20030191075A1
(en)
*
|
2002-02-22 |
2003-10-09 |
Cook Phillip Dan |
Method of using modified oligonucleotides for hepatic delivery
|
US7169916B2
(en)
*
|
2002-04-01 |
2007-01-30 |
Isis Pharmaceuticals, Inc. |
Chloral-free DCA in oligonucleotide synthesis
|
US7199107B2
(en)
|
2002-05-23 |
2007-04-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of kinesin-like 1 expression
|
US20040248094A1
(en)
*
|
2002-06-12 |
2004-12-09 |
Ford Lance P. |
Methods and compositions relating to labeled RNA molecules that reduce gene expression
|
US20100075423A1
(en)
*
|
2002-06-12 |
2010-03-25 |
Life Technologies Corporation |
Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
|
US20040106785A1
(en)
*
|
2002-07-25 |
2004-06-03 |
Micrologix Biotech Inc. |
Inhibitors of RNA dependent RNA polymerase and uses thereof
|
ATE350473T2
(de)
|
2002-08-05 |
2007-01-15 |
Atugen Ag |
Weitere neue formen von interferierende rns moleküle
|
US20040029275A1
(en)
*
|
2002-08-10 |
2004-02-12 |
David Brown |
Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
|
US20050196382A1
(en)
*
|
2002-09-13 |
2005-09-08 |
Replicor, Inc. |
Antiviral oligonucleotides targeting viral families
|
EP2330194A3
(en)
*
|
2002-09-13 |
2011-10-12 |
Replicor, Inc. |
Non-sequence complementary antiviral oligonucleotides
|
AU2003273336A1
(en)
*
|
2002-09-18 |
2004-04-08 |
Isis Pharmaceuticals, Inc. |
Efficient reduction of target rna's by single- and double-stranded oligomeric compounds
|
EP1549767A4
(en)
|
2002-09-26 |
2006-06-07 |
Amgen Inc |
MODULATION OF FORKHEAD BOX O1A GENE EXPRESSION
|
AU2003290596B2
(en)
*
|
2002-11-05 |
2011-05-12 |
Isis Pharmaceuticals, Inc. |
Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
WO2004044138A2
(en)
|
2002-11-05 |
2004-05-27 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
ES2417879T3
(es)
|
2002-11-13 |
2013-08-09 |
Genzyme Corporation |
Modulación antisentido de la expresión de la apolipoproteína B
|
JP4986109B2
(ja)
|
2002-11-13 |
2012-07-25 |
ジェンザイム・コーポレーション |
アポリポタンパク質b発現のアンチセンス調節
|
US7144999B2
(en)
|
2002-11-23 |
2006-12-05 |
Isis Pharmaceuticals, Inc. |
Modulation of hypoxia-inducible factor 1 alpha expression
|
WO2004072284A1
(en)
|
2003-02-11 |
2004-08-26 |
Antisense Therapeutics Ltd |
Modulation of insulin like growth factor i receptor expression
|
US7002006B2
(en)
*
|
2003-02-12 |
2006-02-21 |
Isis Pharmaceuticals, Inc. |
Protection of nucleosides
|
US7803781B2
(en)
|
2003-02-28 |
2010-09-28 |
Isis Pharmaceuticals, Inc. |
Modulation of growth hormone receptor expression and insulin-like growth factor expression
|
US8110674B2
(en)
|
2003-03-07 |
2012-02-07 |
Alnylam Pharmaceuticals, Inc. |
Therapeutic compositions
|
US20040185559A1
(en)
|
2003-03-21 |
2004-09-23 |
Isis Pharmaceuticals Inc. |
Modulation of diacylglycerol acyltransferase 1 expression
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
EP2666858A1
(en)
|
2003-04-17 |
2013-11-27 |
Alnylam Pharmaceuticals Inc. |
Modified iRNA agents
|
US7399853B2
(en)
|
2003-04-28 |
2008-07-15 |
Isis Pharmaceuticals |
Modulation of glucagon receptor expression
|
US20040219533A1
(en)
*
|
2003-04-29 |
2004-11-04 |
Jim Davis |
Biological bar code
|
EP1618215A4
(en)
|
2003-05-01 |
2007-12-05 |
Gen Probe Inc |
OLIGONUCLEOTIDE AS MOLECULAR SWITCH
|
US7897582B2
(en)
|
2003-05-23 |
2011-03-01 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
|
US7960355B2
(en)
|
2003-05-23 |
2011-06-14 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for the modulation of the expression of B7 protein
|
WO2004108081A2
(en)
*
|
2003-06-02 |
2004-12-16 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide synthesis with alternative solvents
|
WO2005002507A2
(en)
|
2003-06-03 |
2005-01-13 |
Isis Pharmaceuticals, Inc. |
Modulation of survivin expression
|
DK2336317T3
(da)
|
2003-06-13 |
2019-12-16 |
Alnylam Europe Ag |
Dobbeltstrenget ribonukleinsyre med forøget effektivitet i en organisme
|
EP1636342A4
(en)
*
|
2003-06-20 |
2008-10-08 |
Isis Pharmaceuticals Inc |
OLIGOMERIC COMPOUNDS FOR GENE MODULATION
|
US7525013B2
(en)
*
|
2003-06-30 |
2009-04-28 |
United Soybean Board |
Soybean selection system based on AEC-resistance
|
US7683036B2
(en)
|
2003-07-31 |
2010-03-23 |
Regulus Therapeutics Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
|
US7825235B2
(en)
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
US20070123480A1
(en)
*
|
2003-09-11 |
2007-05-31 |
Replicor Inc. |
Oligonucleotides targeting prion diseases
|
BRPI0413930A
(pt)
|
2003-09-18 |
2006-10-24 |
Isis Pharmaceuticals Inc |
composto oligomérico ou sal farmaceuticamente aceitável deste, composição farmacêutica ou veterinária, métodos para inibir a expressão de eif4e em uma célula, tecido ou órgão, para diminuir a proliferação de uma célula em que eif4e é expressado, e para prevenir ou tratar uma condição ou doença métodos para prevenir ou diminuir a angiogênese, e o crescimento de tumor em um paciente, oligonucleotìdeo de anti-sentido, composição farmacêutica ou veterinária, e, uso de um composto oligomérico ou sal farmaceuticamente aceitável deste
|
EP1677822B1
(en)
*
|
2003-09-18 |
2014-04-23 |
Isis Pharmaceuticals, Inc. |
4'-thionucleosides and oligomeric compounds
|
US7125945B2
(en)
*
|
2003-09-19 |
2006-10-24 |
Varian, Inc. |
Functionalized polymer for oligonucleotide purification
|
US20050191653A1
(en)
|
2003-11-03 |
2005-09-01 |
Freier Susan M. |
Modulation of SGLT2 expression
|
JP2007520222A
(ja)
|
2004-01-20 |
2007-07-26 |
アイシス ファーマシューティカルズ インコーポレイテッド |
グルココルチコイドレセプター発現の調節
|
US8569474B2
(en)
*
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
US20050244869A1
(en)
*
|
2004-04-05 |
2005-11-03 |
Brown-Driver Vickie L |
Modulation of transthyretin expression
|
AU2005323437B2
(en)
|
2004-04-30 |
2011-10-06 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising a C5-modified pyrimidine
|
US7589184B2
(en)
*
|
2004-05-24 |
2009-09-15 |
Genvault Corporation |
Stable protein storage and stable nucleic acid storage in recoverable form
|
WO2005118806A2
(en)
|
2004-05-28 |
2005-12-15 |
Ambion, Inc. |
METHODS AND COMPOSITIONS INVOLVING MicroRNA
|
US20090048192A1
(en)
*
|
2004-06-03 |
2009-02-19 |
Isis Pharmaceuticals, Inc. |
Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
|
US8394947B2
(en)
*
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
CA2568735A1
(en)
*
|
2004-06-03 |
2005-12-22 |
Isis Pharmaceuticals, Inc. |
Double strand compositions comprising differentially modified strands for use in gene modulation
|
EP1766052A4
(en)
*
|
2004-06-03 |
2009-12-16 |
Isis Pharmaceuticals Inc |
CHIMERIC OLIGOMER COMPOSITIONS WITH CAP
|
US7968762B2
(en)
*
|
2004-07-13 |
2011-06-28 |
Van Andel Research Institute |
Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF)
|
WO2006020768A2
(en)
|
2004-08-10 |
2006-02-23 |
Alnylam Pharmaceuticals, Inc. |
Chemically modified oligonucleotides
|
AU2005277508B2
(en)
|
2004-08-16 |
2011-04-14 |
Quark Pharmaceuticals, Inc |
Therapeutic uses of inhibitors of RTP801
|
WO2006028967A2
(en)
*
|
2004-09-02 |
2006-03-16 |
Yale University |
Regulation of oncogenes by micrornas
|
US7884086B2
(en)
*
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
JP2008513507A
(ja)
|
2004-09-17 |
2008-05-01 |
アイシス ファーマシューティカルズ インコーポレイティッド |
増強されたアンチセンスオリゴヌクレオチド
|
CA2857881A1
(en)
|
2004-11-12 |
2006-12-28 |
Asuragen, Inc. |
Methods and compositions involving mirna and mirna inhibitor molecules
|
WO2008073922A2
(en)
|
2006-12-08 |
2008-06-19 |
Asuragen, Inc. |
Functions and targets of let-7 micro rnas
|
ES2586410T3
(es)
|
2005-02-11 |
2016-10-14 |
Memorial Sloan-Kettering Cancer Center |
Procedimientos y composiciones de detección de un mutante de EGFR resistente a fármacos
|
WO2006110314A2
(en)
|
2005-03-25 |
2006-10-19 |
Ambion, Inc. |
Methods and compositions for depleting abundant rna transcripts
|
JP4773513B2
(ja)
|
2005-05-06 |
2011-09-14 |
ジェン−プローブ・インコーポレーテッド |
A型及びb型インフルエンザウイルスの核酸を検出するための組成物及びアッセイ
|
US8354384B2
(en)
*
|
2005-06-23 |
2013-01-15 |
Yale University |
Anti-aging micrornas
|
US8067571B2
(en)
|
2005-07-13 |
2011-11-29 |
Avi Biopharma, Inc. |
Antibacterial antisense oligonucleotide and method
|
WO2007047912A2
(en)
|
2005-10-17 |
2007-04-26 |
Gen-Probe Incorporated |
Compositions and methods to detect legionella pneumophila nucleic acid
|
EP1941059A4
(en)
|
2005-10-28 |
2010-11-03 |
Alnylam Pharmaceuticals Inc |
COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF THE HUNTINGTIN GENE
|
EP1945270B1
(en)
|
2005-11-09 |
2011-05-25 |
Alnylam Pharmaceuticals Inc. |
Compositions and methods for inhibiting expression of factor v leiden mutant gene
|
UY30097A1
(es)
|
2006-01-20 |
2007-08-31 |
Atugen Ag |
Usos terapeuticos de inhibidores de rtp801
|
EP1984381B1
(en)
*
|
2006-01-27 |
2010-09-29 |
Isis Pharmaceuticals, Inc. |
6-modified bicyclic nucleic acid analogs
|
EP1987166A4
(en)
|
2006-02-03 |
2010-06-02 |
Univ Columbia |
DEOXYRIBOZYME BINARY PROBES FOR ANALYSIS OF NUCLEIC ACID
|
EP2511383B1
(en)
|
2006-03-31 |
2013-12-25 |
Columbia University |
Binary probes for fluorescent analysis of nucleic acids
|
JP5825754B2
(ja)
|
2006-05-05 |
2015-12-02 |
アイシス ファーマシューティカルズ, インコーポレーテッド |
Apobの発現を調節するための化合物および方法
|
US7666854B2
(en)
*
|
2006-05-11 |
2010-02-23 |
Isis Pharmaceuticals, Inc. |
Bis-modified bicyclic nucleic acid analogs
|
NZ572666A
(en)
|
2006-05-11 |
2010-11-26 |
Alnylam Pharmaceuticals Inc |
Compositions comprising double stranded rna and methods for inhibiting expression of the pcsk9 gene
|
ES2389737T3
(es)
*
|
2006-05-11 |
2012-10-31 |
Isis Pharmaceuticals, Inc. |
Análogos de ácidos nucleicos bicíclicos modificados en 5'
|
ATE514794T1
(de)
*
|
2006-05-12 |
2011-07-15 |
Gen Probe Inc |
Zusammensetzungen und verfahren für den nachweis von enterokokken-nukleinsäuren
|
US20090209625A1
(en)
*
|
2006-05-23 |
2009-08-20 |
Sanjay Bhanot |
Modulation of chrebp expression
|
US8198253B2
(en)
|
2006-07-19 |
2012-06-12 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to HBXIP
|
WO2008009477A2
(en)
|
2006-07-21 |
2008-01-24 |
Silence Therapeutics Ag |
Means for inhibiting the expression of protein kinase 3
|
EP2069536B1
(en)
|
2006-08-01 |
2014-11-05 |
Gen-Probe Incorporated |
Methods of nonspecific target capture of nucleic acids
|
CA2664383C
(en)
|
2006-09-19 |
2017-08-22 |
Asuragen, Inc. |
Micrornas differentially expressed in pancreatic diseases and uses thereof
|
CA2663962A1
(en)
|
2006-09-19 |
2008-03-27 |
Asuragen, Inc. |
Mir-15, mir-26, mir-31,mir-145, mir-147, mir-188, mir-215, mir-216, mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
|
US20090209478A1
(en)
|
2006-09-21 |
2009-08-20 |
Tomoko Nakayama |
Compositions and methods for inhibiting expression of the hamp gene
|
CA2927045A1
(en)
|
2006-10-03 |
2008-04-10 |
Muthiah Manoharan |
Lipid containing formulations
|
JP2010507387A
(ja)
|
2006-10-25 |
2010-03-11 |
クアーク・ファーマスーティカルス、インコーポレイテッド |
新規のsiRNAおよびその使用方法
|
US20100062436A1
(en)
|
2006-10-31 |
2010-03-11 |
Noxxon Pharma Ag |
Methods for Detection of a Single- or Double-Stranded Nucleic Acid Molecule
|
EP3095873B1
(en)
|
2006-12-21 |
2018-04-18 |
Gen-Probe Incorporated |
Methods and compositions for nucleic acid amplification
|
EP2114981B1
(en)
|
2007-01-29 |
2013-05-08 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating protein expression
|
PE20090064A1
(es)
|
2007-03-26 |
2009-03-02 |
Novartis Ag |
Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
|
BRPI0810336A2
(pt)
|
2007-05-11 |
2019-03-19 |
The Trustees Of The University Of Pennsylvania |
"método para tratar e/ou prevenir úlceras de pele em um indivíduo"
|
AU2007353454C8
(en)
|
2007-05-11 |
2014-04-24 |
Rowan University |
Methods of treatment and prevention of neurodegenerative diseases and disorders
|
CA2688321A1
(en)
|
2007-05-30 |
2008-12-11 |
Isis Pharmaceuticals, Inc. |
N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
|
WO2008154401A2
(en)
|
2007-06-08 |
2008-12-18 |
Isis Pharmaceuticals, Inc. |
Carbocyclic bicyclic nucleic acid analogs
|
CA2691364C
(en)
|
2007-06-19 |
2020-06-16 |
Stratos Genomics, Inc. |
High throughput nucleic acid sequencing by expansion
|
AU2008270209B2
(en)
|
2007-07-05 |
2012-05-17 |
Arrowhead Pharmaceuticals, Inc. |
dsRNA for treating viral infection
|
ATE538127T1
(de)
*
|
2007-07-05 |
2012-01-15 |
Isis Pharmaceuticals Inc |
6-disubstituierte bicyclische nukleinsäureanaloga
|
CN101821277B
(zh)
|
2007-08-15 |
2014-05-07 |
Isis制药公司 |
四氢吡喃核酸类似物
|
JP2010539978A
(ja)
|
2007-10-02 |
2010-12-24 |
アムジェン インコーポレイテッド |
マイクロ−rnaおよびその前駆体にハイブリダイズしうる核酸を用いるエリスロポエチンの増加
|
JP5646997B2
(ja)
|
2007-10-03 |
2014-12-24 |
クォーク ファーマシューティカルズ インコーポレーティッドQuark Pharmaceuticals,Inc. |
新規siRNA構造
|
US8916531B2
(en)
*
|
2007-11-20 |
2014-12-23 |
Isis Pharmaceuticals, Inc. |
Modulation of CD40 expression
|
CA2708173C
(en)
|
2007-12-04 |
2016-02-02 |
Alnylam Pharmaceuticals, Inc. |
Targeting lipids
|
CA2715991A1
(en)
*
|
2007-12-26 |
2009-07-09 |
Gen-Probe Incorporated |
Amplification oligomers and methods to detect candida albicans 26s rrna or encoding dna
|
US9605035B2
(en)
|
2008-01-10 |
2017-03-28 |
Research Development Foundation |
Vaccines and diagnostics for the ehrlichioses
|
US8530640B2
(en)
*
|
2008-02-07 |
2013-09-10 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexitol nucleic acid analogs
|
AU2009222056A1
(en)
*
|
2008-03-01 |
2009-09-11 |
Abraxis Bioscience, Llc |
Treatment, diagnostic, and method for discovering antagonist using SPARC specific miRNAs
|
EP2282744B1
(en)
|
2008-03-21 |
2018-01-17 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising tricyclic nucleosides and methods for their use
|
US8846639B2
(en)
*
|
2008-04-04 |
2014-09-30 |
Isis Pharmaceutical, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
|
EP2285819B1
(en)
*
|
2008-04-04 |
2013-10-16 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides
|
WO2009126933A2
(en)
|
2008-04-11 |
2009-10-15 |
Alnylam Pharmaceuticals, Inc. |
Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
|
WO2009137660A2
(en)
*
|
2008-05-07 |
2009-11-12 |
Abraxis Bioscience, Llc |
Enhancement of drug therapy by mirna
|
US8258111B2
(en)
|
2008-05-08 |
2012-09-04 |
The Johns Hopkins University |
Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
|
US20100209957A1
(en)
*
|
2008-06-20 |
2010-08-19 |
Genvault Corporation |
Biosample storage devices and methods of use thereof
|
EP2323667A4
(en)
*
|
2008-08-07 |
2012-07-25 |
Isis Pharmaceuticals Inc |
MODULATION OF TRANSTHYRETIN EXPRESSION BY TREATMENT OF CNS DISEASES
|
US8283165B2
(en)
|
2008-09-12 |
2012-10-09 |
Genvault Corporation |
Matrices and media for storage and stabilization of biomolecules
|
AU2009298802A1
(en)
|
2008-09-23 |
2010-04-08 |
Alnylam Pharmaceuticals, Inc. |
Chemical modifications of monomers and oligonucleotides with cycloaddition
|
US8604192B2
(en)
*
|
2008-09-24 |
2013-12-10 |
Isis Pharmaceuticals, Inc. |
Cyclohexenyl nucleic acids analogs
|
EP2356129B1
(en)
*
|
2008-09-24 |
2013-04-03 |
Isis Pharmaceuticals, Inc. |
Substituted alpha-l-bicyclic nucleosides
|
CN103820450B
(zh)
|
2008-10-15 |
2018-08-21 |
Ionis制药公司 |
因子11表达的调节
|
US8987435B2
(en)
|
2008-10-24 |
2015-03-24 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and methods
|
JP5763539B2
(ja)
|
2008-10-24 |
2015-08-12 |
アイシス ファーマシューティカルズ, インコーポレーテッド |
5’及び2’ビス置換ヌクレオシド及びそれから製造されるオリゴマー化合物
|
US20100135904A1
(en)
|
2008-11-07 |
2010-06-03 |
Research Development Foundation |
Compositions and methods for the inhibition of cripto / grp78 complex formation and signaling
|
CA2743139C
(en)
|
2008-11-10 |
2019-04-02 |
Alnylam Pharmaceuticals, Inc. |
Novel lipids and compositions for the delivery of therapeutics
|
US8551768B2
(en)
|
2008-11-21 |
2013-10-08 |
The Trustees Of Columbia University In The City Of New York |
Split DNA enzyme for visual single nucleotide polymorphism typing
|
JP5645840B2
(ja)
|
2008-12-02 |
2014-12-24 |
株式会社Wave Life Sciences Japan |
リン原子修飾核酸の合成方法
|
US20110288155A1
(en)
|
2008-12-18 |
2011-11-24 |
Elena Feinstein |
Sirna compounds and methods of use thereof
|
US8853134B2
(en)
|
2009-01-28 |
2014-10-07 |
The Trustees Of Columbia University In The City Of New York |
Microarrays of binary nucleic acid probes for detecting nucleic acid analytes
|
EP2393825A2
(en)
|
2009-02-06 |
2011-12-14 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and methods
|
WO2010090969A1
(en)
|
2009-02-06 |
2010-08-12 |
Isis Pharmaceuticals, Inc. |
Tetrahydropyran nucleic acid analogs
|
WO2010091878A2
(en)
|
2009-02-13 |
2010-08-19 |
Silence Therapeutics Ag |
Means for inhibiting the expression of opa1
|
JP2012517815A
(ja)
|
2009-02-18 |
2012-08-09 |
サイレンス・セラピューティクス・アーゲー |
Ang2の発現を阻害するための手段
|
EP3424939A1
(en)
|
2009-03-02 |
2019-01-09 |
Alnylam Pharmaceuticals Inc. |
Nucleic acid chemical modifications
|
EA201190178A1
(ru)
*
|
2009-03-20 |
2012-06-29 |
Алиос Биофарма, Инк. |
Замещённые нуклеозидные и нуклеотидные аналоги
|
US20110045080A1
(en)
*
|
2009-03-24 |
2011-02-24 |
William Marsh Rice University |
Single-Walled Carbon Nanotube/Bioactive Substance Complexes and Methods Related Thereto
|
EP2258858A1
(en)
|
2009-06-05 |
2010-12-08 |
Universitätsklinikum Freiburg |
Transgenic LSD1 animal model for cancer
|
TR201811076T4
(tr)
|
2009-06-10 |
2018-08-27 |
Arbutus Biopharma Corp |
Geliştirilmiş lipit formulasyonu.
|
WO2011003020A1
(en)
|
2009-07-01 |
2011-01-06 |
Gen-Probe Incorporated |
Methods and compositions for nucleic acid amplification
|
EP2451461A4
(en)
|
2009-07-06 |
2013-05-29 |
Ontorii Inc |
NOVEL NUCLEIC ACID PRODRUGS AND METHOD OF USE THEREOF
|
WO2011005861A1
(en)
|
2009-07-07 |
2011-01-13 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotide end caps
|
US8927513B2
(en)
|
2009-07-07 |
2015-01-06 |
Alnylam Pharmaceuticals, Inc. |
5′ phosphate mimics
|
EP2462153B1
(en)
|
2009-08-06 |
2015-07-29 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexose nucleic acid analogs
|
EP2464336A4
(en)
|
2009-08-14 |
2013-11-20 |
Alnylam Pharmaceuticals Inc |
COMPOSITIONS FORMULATED IN LIPIDS AND METHODS OF INHIBITING THE EXPRESSION OF EBOLA VIRUS GENE
|
TW201124160A
(en)
|
2009-11-26 |
2011-07-16 |
Quark Pharmaceuticals Inc |
SiRNA compounds comprising terminal substitutions
|
CA3044884A1
(en)
|
2009-12-07 |
2011-06-16 |
Arbutus Biopharma Corporation |
Compositions for nucleic acid delivery
|
EP2862929B1
(en)
|
2009-12-09 |
2017-09-06 |
Quark Pharmaceuticals, Inc. |
Compositions and methods for treating diseases, disorders or injury of the CNS
|
CN106701758B
(zh)
|
2009-12-09 |
2020-02-07 |
日东电工株式会社 |
Hsp47表达的调节
|
EP2512449B1
(en)
|
2009-12-18 |
2019-08-07 |
The University of British Columbia |
Methods and compositions for delivery of nucleic acids
|
WO2011084193A1
(en)
|
2010-01-07 |
2011-07-14 |
Quark Pharmaceuticals, Inc. |
Oligonucleotide compounds comprising non-nucleotide overhangs
|
US8779118B2
(en)
|
2010-01-11 |
2014-07-15 |
Isis Pharmaceuticals, Inc. |
Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
|
WO2011094580A2
(en)
|
2010-01-28 |
2011-08-04 |
Alnylam Pharmaceuticals, Inc. |
Chelated copper for use in the preparation of conjugated oligonucleotides
|
US9198972B2
(en)
|
2010-01-28 |
2015-12-01 |
Alnylam Pharmaceuticals, Inc. |
Monomers and oligonucleotides comprising cycloaddition adduct(s)
|
WO2011103274A1
(en)
|
2010-02-17 |
2011-08-25 |
Gen-Probe Incorporated |
Compositions and methods to detect atopobium vaginae nucleic acid
|
ES2631458T3
(es)
|
2010-03-04 |
2017-08-31 |
Interna Technologies B.V. |
Molécula de ARNmi definida por su fuente y sus usos terapéuticos en el cáncer asociado a la EMT
|
WO2011115818A1
(en)
|
2010-03-17 |
2011-09-22 |
Isis Pharmaceuticals, Inc. |
5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
|
WO2011123621A2
(en)
|
2010-04-01 |
2011-10-06 |
Alnylam Pharmaceuticals Inc. |
2' and 5' modified monomers and oligonucleotides
|
WO2011133811A2
(en)
|
2010-04-21 |
2011-10-27 |
Gen-Probe Incorporated |
Compositions, methods and kits to detect herpes simplex virus nucleic acid
|
WO2011133876A2
(en)
|
2010-04-22 |
2011-10-27 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising acyclic and abasic nucleosides and analogs
|
US9725479B2
(en)
|
2010-04-22 |
2017-08-08 |
Ionis Pharmaceuticals, Inc. |
5′-end derivatives
|
US20130260460A1
(en)
|
2010-04-22 |
2013-10-03 |
Isis Pharmaceuticals Inc |
Conformationally restricted dinucleotide monomers and oligonucleotides
|
JP6005628B2
(ja)
|
2010-04-28 |
2016-10-12 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
修飾ヌクレオシド、その類似体、およびこれらから調製されるオリゴマー化合物
|
EP2625186B1
(en)
|
2010-04-28 |
2016-07-27 |
Ionis Pharmaceuticals, Inc. |
5' modified nucleosides and oligomeric compounds prepared therefrom
|
WO2011139695A2
(en)
|
2010-04-28 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Modified 5' diphosphate nucleosides and oligomeric compounds prepared therefrom
|
WO2011139911A2
(en)
|
2010-04-29 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Lipid formulated single stranded rna
|
KR20180026798A
(ko)
|
2010-04-29 |
2018-03-13 |
아이오니스 파마수티컬즈, 인코포레이티드 |
트랜스티레틴 발현의 조절
|
JP2013530154A
(ja)
|
2010-05-28 |
2013-07-25 |
サレプタ セラピューティクス, インコーポレイテッド |
修飾されたサブユニット間結合および/または末端基を有するオリゴヌクレオチドアナログ
|
US8957200B2
(en)
|
2010-06-07 |
2015-02-17 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
EP2580228B1
(en)
|
2010-06-08 |
2016-03-23 |
Ionis Pharmaceuticals, Inc. |
Substituted 2'-amino and 2'-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
WO2011163436A1
(en)
|
2010-06-24 |
2011-12-29 |
Quark Pharmaceuticals, Inc. |
Double stranded rna compounds to rhoa and use thereof
|
CA2802741C
(en)
|
2010-06-30 |
2020-07-07 |
Gen-Probe Incorporated |
Method and apparatus for identifying analyte-containing samples using single-read determination of analyte and process control signals
|
CA2804599C
(en)
|
2010-07-06 |
2023-01-31 |
Interna Technologies Bv |
Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
|
EP3301195B1
(en)
|
2010-07-12 |
2022-11-02 |
Gen-Probe Incorporated |
Compositions and assays to detect 2009 swine h1n1 influenza a virus nucleic acid
|
WO2012016184A2
(en)
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
US20130202652A1
(en)
|
2010-07-30 |
2013-08-08 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
CN103328500B
(zh)
|
2010-08-04 |
2018-01-26 |
西兹尔生物技术有限公司 |
用于癌症的诊断和治疗的方法和化合物
|
WO2012030856A2
(en)
|
2010-08-30 |
2012-03-08 |
Gen-Probe Incorporated |
Compositions, methods and reaction mixtures for the detection of xenotropic murine leukemia virus-related virus
|
WO2012031243A2
(en)
|
2010-09-03 |
2012-03-08 |
Avi Biopharma, Inc. |
dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
|
EP2616555B1
(en)
|
2010-09-16 |
2017-11-08 |
Gen-Probe Incorporated |
Capture probes immobilizable via l-nucleotide tail
|
CN103209987B
(zh)
|
2010-09-22 |
2017-06-06 |
艾丽奥斯生物制药有限公司 |
取代的核苷酸类似物
|
EP2620428B1
(en)
|
2010-09-24 |
2019-05-22 |
Wave Life Sciences Ltd. |
Asymmetric auxiliary group
|
EP2625297B1
(en)
|
2010-10-04 |
2018-10-10 |
Gen-Probe Prodesse, Inc. |
Compositions, methods and kits to detect adenovirus nucleic acids
|
US20140134231A1
(en)
|
2010-10-11 |
2014-05-15 |
Sanford-Burnham Medical Research Institute |
Mir-211 expression and related pathways in human melanoma
|
EP2635703B1
(en)
|
2010-11-01 |
2018-03-21 |
Gen-Probe Incorporated |
Integrated capture and amplification of target nucleic acid for sequencing
|
US8569220B2
(en)
|
2010-11-12 |
2013-10-29 |
Jelmar, Llc |
Hard surface cleaning composition
|
AU2011329777B2
(en)
|
2010-11-17 |
2016-06-09 |
Ionis Pharmaceuticals, Inc. |
Modulation of alpha synuclein expression
|
SG190412A1
(en)
|
2010-12-06 |
2013-06-28 |
Quark Pharmaceuticals Inc |
Double stranded oligonucleotide compounds comprising threose modifications
|
EP2474617A1
(en)
|
2011-01-11 |
2012-07-11 |
InteRNA Technologies BV |
Mir for treating neo-angiogenesis
|
WO2012099755A1
(en)
|
2011-01-11 |
2012-07-26 |
Alnylam Pharmaceuticals, Inc. |
Pegylated lipids and their use for drug delivery
|
KR101937498B1
(ko)
|
2011-03-03 |
2019-04-10 |
쿠아크 파마수티칼스 인코퍼레이티드 |
폐 질환 및 손상을 치료하기 위한 조성물 및 방법
|
CN103562387A
(zh)
|
2011-03-03 |
2014-02-05 |
夸克医药公司 |
Toll样受体途径的寡核苷酸调剂
|
EP2683833B1
(en)
|
2011-03-10 |
2018-09-26 |
Gen-Probe Incorporated |
Methods for the selection and optimization of oligonucleotide tag sequences
|
AU2012249751B2
(en)
|
2011-04-25 |
2016-11-03 |
Gen-Probe Incorporated |
Compositions and methods for detecting BV-associated bacterial nucleic acid
|
US10196637B2
(en)
|
2011-06-08 |
2019-02-05 |
Nitto Denko Corporation |
Retinoid-lipid drug carrier
|
TWI658830B
(zh)
|
2011-06-08 |
2019-05-11 |
日東電工股份有限公司 |
Hsp47表現調控強化用類視色素脂質體
|
WO2012170347A1
(en)
|
2011-06-09 |
2012-12-13 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
WO2013003697A1
(en)
|
2011-06-30 |
2013-01-03 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
AU2012284307A1
(en)
|
2011-07-15 |
2013-05-09 |
Gen-Probe Incorporated |
Compositions and method for detecting human parvovirus nucleic acid and for detecting hepatitis A virus nucleic acids in single-plex or multiplex assays
|
US9605019B2
(en)
|
2011-07-19 |
2017-03-28 |
Wave Life Sciences Ltd. |
Methods for the synthesis of functionalized nucleic acids
|
EP4269584A3
(en)
|
2011-08-11 |
2024-03-27 |
Ionis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
WO2013033230A1
(en)
|
2011-08-29 |
2013-03-07 |
Isis Pharmaceuticals, Inc. |
Oligomer-conjugate complexes and their use
|
AU2012304537B2
(en)
|
2011-09-06 |
2015-08-20 |
Gen-Probe Incorporated |
Closed nucleic acid structures
|
AU2012304520B2
(en)
|
2011-09-06 |
2016-06-16 |
Gen-Probe Incorporated |
Circularized templates for sequencing
|
US9663829B2
(en)
|
2011-09-08 |
2017-05-30 |
Gen-Probe Incorporated |
Compositions and methods for detecting BV-associated bacterial nucleic acid
|
WO2013040251A2
(en)
|
2011-09-13 |
2013-03-21 |
Asurgen, Inc. |
Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
|
JP6250543B2
(ja)
|
2011-09-27 |
2017-12-20 |
アルニラム・ファーマシューティカルズ・インコーポレーテッド |
ジ脂肪族置換peg化脂質
|
US20130157884A1
(en)
|
2011-10-26 |
2013-06-20 |
Asuragen, Inc. |
Methods and compositions involving mirna expression levels for distinguishing pancreatic cysts
|
SG11201401648RA
(en)
|
2011-11-03 |
2014-05-29 |
Quark Pharmaceuticals Inc |
Methods and compositions for neuroprotection
|
EP3492604B1
(en)
|
2011-11-04 |
2021-01-06 |
Gen-Probe Incorporated |
Molecular assay reagents and methods
|
US20140323549A1
(en)
|
2011-11-08 |
2014-10-30 |
Quark Pharmaceuticals, Inc. |
Methods and compositions for treating diseases, disorders or injury of the nervous system
|
CN111808135A
(zh)
|
2011-11-18 |
2020-10-23 |
萨勒普塔医疗公司 |
功能改性的寡核苷酸及其亚单元
|
DE102011120550B4
(de)
|
2011-12-05 |
2013-11-07 |
Gen-Probe Prodesse, Inc. |
Zusammensetzungen, Verfahren und Kits zur Detektion von Adenovirusnukleinsäuren
|
EP2794630A4
(en)
|
2011-12-22 |
2015-04-01 |
Alios Biopharma Inc |
SUBSTITUTED PHOSPHORTHIOAT NUCLEOTIDE ANALOGUE
|
EP3369818B1
(en)
|
2011-12-22 |
2021-06-09 |
InteRNA Technologies B.V. |
Mirna for treating head and neck cancer
|
CN107459544B
(zh)
|
2011-12-22 |
2021-03-16 |
詹森生物制药有限公司 |
取代的核苷、核苷酸及其类似物
|
US20150216998A1
(en)
|
2012-01-01 |
2015-08-06 |
Ramot At Tel-Aviv University Ltd. |
Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents
|
RU2014125496A
(ru)
|
2012-01-12 |
2016-02-27 |
Кварк Фармасьютикалс, Инк. |
Комбинированная терапия для лечения нарушений слуха и равновесия
|
AU2013205603B2
(en)
|
2012-02-01 |
2016-03-17 |
Gen-Probe Incorporated |
Asymmetric hairpin target capture oligomers
|
WO2013123996A1
(en)
|
2012-02-24 |
2013-08-29 |
Astrazeneca Uk Limited |
Novel sirna inhibitors of human icam-1
|
CA2866166C
(en)
|
2012-03-09 |
2023-10-17 |
Vestaron Corporation |
Toxic peptide production, peptide expression in plants and combinations of cysteine rich peptides
|
EP2639238A1
(en)
|
2012-03-15 |
2013-09-18 |
Universität Bern |
Tricyclic nucleosides and oligomeric compounds prepared therefrom
|
CN104321333A
(zh)
|
2012-03-21 |
2015-01-28 |
沃泰克斯药物股份有限公司 |
硫代氨基磷酸酯核苷酸前药的固体形式
|
US9441007B2
(en)
|
2012-03-21 |
2016-09-13 |
Alios Biopharma, Inc. |
Substituted nucleosides, nucleotides and analogs thereof
|
USRE48171E1
(en)
|
2012-03-21 |
2020-08-25 |
Janssen Biopharma, Inc. |
Substituted nucleosides, nucleotides and analogs thereof
|
NZ630805A
(en)
|
2012-03-22 |
2016-01-29 |
Alios Biopharma Inc |
Pharmaceutical combinations comprising a thionucleotide analog
|
WO2013154799A1
(en)
|
2012-04-09 |
2013-10-17 |
Isis Pharmaceuticals, Inc. |
Tricyclic nucleosides and oligomeric compounds prepared therefrom
|
EP2850092B1
(en)
|
2012-04-09 |
2017-03-01 |
Ionis Pharmaceuticals, Inc. |
Tricyclic nucleic acid analogs
|
AU2013205110B2
(en)
|
2012-04-24 |
2016-10-13 |
Gen-Probe Incorporated |
Compositions, Methods and Kits to Detect Herpes Simplex Virus Nucleic Acids
|
US9994604B2
(en)
|
2012-05-31 |
2018-06-12 |
Bio-Lab Ltd. |
Pyrazolotriazolyl nucleoside analogues and oligonucleotides comprising them
|
AU2013205064B2
(en)
|
2012-06-04 |
2015-07-30 |
Gen-Probe Incorporated |
Compositions and Methods for Amplifying and Characterizing HCV Nucleic Acid
|
BR112015000784A8
(pt)
|
2012-07-13 |
2018-04-03 |
Wave Life Sciences Japan |
Grupo auxiliar assimétrico
|
AU2013205087B2
(en)
|
2012-07-13 |
2016-03-03 |
Gen-Probe Incorporated |
Method for detecting a minority genotype
|
AU2013202793B2
(en)
|
2012-07-31 |
2014-09-18 |
Gen-Probe Incorporated |
System, method and apparatus for automated incubation
|
ES2761920T3
(es)
|
2012-08-30 |
2020-05-21 |
Gen Probe Inc |
Amplificación de ácido nucleico multifásica
|
WO2014043291A1
(en)
|
2012-09-12 |
2014-03-20 |
Quark Pharmaceuticals, Inc. |
Double-stranded nucleic acid compounds
|
AU2013315524B2
(en)
|
2012-09-12 |
2019-01-31 |
Quark Pharmaceuticals, Inc. |
Double-stranded oligonucleotide molecules to p53 and methods of use thereof
|
DK2895607T3
(da)
|
2012-09-12 |
2021-05-25 |
Quark Pharmaceuticals Inc |
Dobbeltstrengede oligonukleotidmolekyler til ddit4 og fremgangsmåder til anvendelse deraf
|
WO2014045126A2
(en)
|
2012-09-18 |
2014-03-27 |
Uti Limited Partnership |
Treatment of pain by inhibition of usp5 de-ubiquitinase
|
US20140100124A1
(en)
|
2012-10-04 |
2014-04-10 |
Asuragen, Inc. |
Diagnostic mirnas for differential diagnosis of incidental pancreatic cystic lesions
|
AU2013205122B2
(en)
|
2012-10-11 |
2016-11-10 |
Gen-Probe Incorporated |
Compositions and Methods for Detecting Human Papillomavirus Nucleic Acid
|
US9029335B2
(en)
|
2012-10-16 |
2015-05-12 |
Isis Pharmaceuticals, Inc. |
Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
EP3800256A1
(en)
|
2012-11-06 |
2021-04-07 |
InteRNA Technologies B.V. |
Combination to be used in therapeutic use against diseases or conditions associated with melanoma, or in diseases or conditions associated with activated b-raf pathway
|
AU2013205090B2
(en)
|
2012-12-07 |
2016-07-28 |
Gen-Probe Incorporated |
Compositions and Methods for Detecting Gastrointestinal Pathogen Nucleic Acid
|
EP2961853B1
(en)
|
2013-02-28 |
2018-09-19 |
The Board of Regents of The University of Texas System |
Methods for classifying a cancer as susceptible to tmepai-directed therapies and treating such cancers
|
CA2905144C
(en)
|
2013-03-14 |
2023-08-22 |
Lyle J. Arnold |
Methods for amplification of nucleic acids on solid support
|
CN105209640A
(zh)
|
2013-03-15 |
2015-12-30 |
莱尔·J·阿诺德 |
使用发卡寡核苷酸扩增核酸的方法
|
CN105247076B
(zh)
|
2013-03-15 |
2021-06-18 |
莱尔·J·阿诺德 |
使用拼装序列扩增片段化的目标核酸的方法
|
WO2014144666A2
(en)
|
2013-03-15 |
2014-09-18 |
The University Of Chicago |
Methods and compositions related to t-cell activity
|
EP3708184A1
(en)
|
2013-03-27 |
2020-09-16 |
The General Hospital Corporation |
Methods and agents for treating alzheimer s disease
|
CN105378085B
(zh)
|
2013-05-01 |
2019-02-15 |
Ionis制药公司 |
用于调节hbv和ttr表达的组合物和方法
|
CN105452465B
(zh)
|
2013-07-31 |
2019-06-21 |
奇比艾企业有限公司 |
鞘脂-聚烷基胺-寡核苷酸化合物
|
US20160208247A1
(en)
|
2013-07-31 |
2016-07-21 |
Qbi Enterprises Ltd. |
Methods of use of sphingolipid polyalkylamine oligonucleotide compounds
|
EP3033437B1
(en)
|
2013-08-14 |
2023-11-08 |
Gen-Probe Incorporated |
Compositions and methods for detecting hev nucleic acid
|
EP2853595A1
(en)
|
2013-09-30 |
2015-04-01 |
Soluventis GmbH |
NOTCH 1 specific siRNA molecules
|
US11162096B2
(en)
|
2013-10-14 |
2021-11-02 |
Ionis Pharmaceuticals, Inc |
Methods for modulating expression of C9ORF72 antisense transcript
|
EP3065706A4
(en)
|
2013-11-08 |
2017-11-29 |
Baylor Research Institute |
Nuclear localization of glp-1 stimulates myocardial regeneration and reverses heart failure
|
US20170268000A1
(en)
|
2013-12-02 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds and uses thereof
|
CN113278617A
(zh)
|
2014-01-16 |
2021-08-20 |
波涛生命科学有限公司 |
手性设计
|
WO2015123551A1
(en)
|
2014-02-13 |
2015-08-20 |
Du Luqin |
Microrna composition for the treatment of neuroblastoma
|
EP3119789B1
(en)
|
2014-03-17 |
2020-04-22 |
Ionis Pharmaceuticals, Inc. |
Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom
|
WO2015143245A1
(en)
|
2014-03-19 |
2015-09-24 |
Isis Pharmaceuticals, Inc. |
Methods for modulating ataxin 2 expression
|
SG10201808063PA
(en)
|
2014-03-19 |
2018-10-30 |
Ionis Pharmaceuticals Inc |
Compositions for modulating ataxin 2 expression
|
MX2016012922A
(es)
|
2014-04-01 |
2017-01-26 |
Ionis Pharmaceuticals Inc |
Composiciones para modular la expresion de sod-1.
|
US10221416B2
(en)
|
2014-04-24 |
2019-03-05 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising alpha-beta-constrained nucleic acid
|
EP3137476B1
(en)
|
2014-04-28 |
2019-10-09 |
Ionis Pharmaceuticals, Inc. |
Linkage modified oligomeric compounds
|
MX2016014102A
(es)
|
2014-05-01 |
2017-05-03 |
Ionis Pharmaceuticals Inc |
Composiciones y metodos para modular la expresion de similar a la angiopoyetina tipo 3.
|
PE20190626A1
(es)
|
2014-05-01 |
2019-04-26 |
Ionis Pharmaceuticals Inc |
Composiciones y metodos para modular la expresion del factor b del complemento
|
KR102524543B1
(ko)
|
2014-06-10 |
2023-04-20 |
에라스무스 유니버시티 메디컬 센터 로테르담 |
폼페병의 치료에 유용한 안티센스 올리고뉴클레오티드
|
WO2016033424A1
(en)
|
2014-08-29 |
2016-03-03 |
Genzyme Corporation |
Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
|
JP6841753B2
(ja)
|
2014-09-15 |
2021-03-10 |
ザ チルドレンズ メディカル センター コーポレーション |
ヒストンh3−リジントリメチル化を除去することによって体細胞核移入(scnt)効率を増加させるための方法および組成物
|
WO2016057693A1
(en)
|
2014-10-10 |
2016-04-14 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhalation delivery of conjugated oligonucleotide
|
GB2536745B
(en)
|
2014-10-20 |
2019-06-26 |
Gen Probe Inc |
Red Blood cell lysis solution
|
WO2016083624A1
(en)
|
2014-11-28 |
2016-06-02 |
Silence Therapeutics Gmbh |
Means for inhibiting the expression of edn1
|
EP3230445B1
(en)
|
2014-12-12 |
2024-01-24 |
Tod M. Woolf |
Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides
|
AU2015364508A1
(en)
|
2014-12-18 |
2017-07-06 |
Alnylam Pharmaceuticals, Inc. |
ReversirTM compounds
|
US9688707B2
(en)
|
2014-12-30 |
2017-06-27 |
Ionis Pharmaceuticals, Inc. |
Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
|
WO2016112132A1
(en)
|
2015-01-06 |
2016-07-14 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
JP6944873B2
(ja)
|
2015-01-09 |
2021-10-06 |
ジェン−プローブ・インコーポレーテッド |
細菌性膣症を診断するための方法および組成物
|
US10538763B2
(en)
|
2015-01-16 |
2020-01-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of DUX4
|
EP3259346A4
(en)
|
2015-02-20 |
2018-07-11 |
Baylor College of Medicine |
P63 inactivation for the treatment of heart failure
|
US11129844B2
(en)
|
2015-03-03 |
2021-09-28 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating MECP2 expression
|
US10550438B2
(en)
|
2015-03-16 |
2020-02-04 |
Gen-Probe Incorporated |
Methods and compositions for detecting bacterial nucleic acid
|
WO2016167780A1
(en)
|
2015-04-16 |
2016-10-20 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
WO2016196897A1
(en)
|
2015-06-04 |
2016-12-08 |
Sarepta Therapeutics, Inc. |
Methods and compounds for treatment of lymphocyte-related diseases and conditions
|
AU2016295168B2
(en)
|
2015-07-17 |
2021-08-19 |
Alnylam Pharmaceuticals, Inc. |
Multi-targeted single entity conjugates
|
WO2017053781A1
(en)
|
2015-09-25 |
2017-03-30 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating ataxin 3 expression
|
MX2018004637A
(es)
|
2015-10-14 |
2019-05-06 |
Bio Path Holdings Inc |
Ácidos nucleicos p-etoxi para formulacion liposomal.
|
US10557137B2
(en)
|
2015-11-06 |
2020-02-11 |
Ionis Pharmaceuticals, Inc. |
Modulating apolipoprotein (a) expression
|
WO2017096395A1
(en)
|
2015-12-04 |
2017-06-08 |
Ionis Pharmaceuticals, Inc. |
Methods of treating breast cancer
|
AU2015416656B2
(en)
|
2015-12-07 |
2023-02-23 |
Erasmus University Medical Center Rotterdam |
Enzymatic replacement therapy and antisense therapy for Pompe disease
|
EP4249609A3
(en)
|
2016-01-04 |
2023-12-20 |
Gen-Probe Incorporated |
Methods and compositions for detecting candida species
|
US10907160B2
(en)
|
2016-01-05 |
2021-02-02 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing LRRK2 expression
|
US10577607B2
(en)
|
2016-03-16 |
2020-03-03 |
Ionis Pharmaceuticals, Inc. |
Modulation of DYRK1B expression
|
CA3013799A1
(en)
|
2016-03-16 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Methods of modulating keap1
|
EP3436049B1
(en)
|
2016-03-31 |
2022-01-12 |
Baylor Research Institute |
Angiopoietin-like protein 8 (angptl8)
|
EP3228326A1
(en)
|
2016-04-05 |
2017-10-11 |
Silence Therapeutics GmbH |
Nucleic acid linked to a trivalent glycoconjugate
|
US11365415B2
(en)
|
2016-04-14 |
2022-06-21 |
University Of Florida Research Foundation, Inc. |
Use of miR-223-3p as a cancer therapeutic and method for treating cancer using the same
|
US11236339B2
(en)
|
2016-06-17 |
2022-02-01 |
Ionis Pharmaceuticals, Inc. |
Modulation of GYS1 expression
|
NL2017295B1
(en)
|
2016-08-05 |
2018-02-14 |
Univ Erasmus Med Ct Rotterdam |
Antisense oligomeric compound for Pompe disease
|
NL2017294B1
(en)
|
2016-08-05 |
2018-02-14 |
Univ Erasmus Med Ct Rotterdam |
Natural cryptic exon removal by pairs of antisense oligonucleotides.
|
SG10202008771WA
(en)
|
2016-09-16 |
2020-10-29 |
Bio Path Holdings Inc |
Combination therapy with liposomal antisense oligonucleotides
|
WO2018067900A1
(en)
|
2016-10-06 |
2018-04-12 |
Ionis Pharmaceuticals, Inc. |
Method of conjugating oligomeric compounds
|
AU2017346854A1
(en)
|
2016-10-19 |
2019-05-30 |
Gen-Probe Incorporated |
Compositions and methods for detecting or quantifying hepatitis C virus
|
JOP20190104A1
(ar)
|
2016-11-10 |
2019-05-07 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن atxn3
|
US10508313B2
(en)
|
2016-11-21 |
2019-12-17 |
Gen-Probe Incorporated |
Compositions and methods for detecting or quantifying Hepatitis B virus
|
US11033570B2
(en)
|
2016-12-02 |
2021-06-15 |
Cold Spring Harbor Laboratory |
Modulation of Lnc05 expression
|
AU2017379073B2
(en)
|
2016-12-22 |
2023-12-14 |
Intellia Therapeutics, Inc. |
Compositions and methods for treating alpha-1 antitrypsin deficiency
|
US11197928B2
(en)
|
2017-01-13 |
2021-12-14 |
Board Of Regents, The University Of Texas System |
Sustained production of high affinity antigen specific antibody by high dose BAFF receptor-targeting mAb-siRNA conjugate
|
US11180756B2
(en)
|
2017-03-09 |
2021-11-23 |
Ionis Pharmaceuticals |
Morpholino modified oligomeric compounds
|
EP3601617B3
(en)
|
2017-03-24 |
2024-03-20 |
Gen-Probe Incorporated |
Compositions and methods for detecting or quantifying parainfluenza virus
|
EP4219768A3
(en)
|
2017-03-25 |
2023-10-11 |
Gen-Probe Incorporated |
Compositions, methods and kits to detect metapneumovirus nucleic acids
|
WO2018185252A1
(en)
|
2017-04-05 |
2018-10-11 |
Silence Therapeutics Gmbh |
Nucleic acid conjugates
|
WO2018185253A1
(en)
|
2017-04-05 |
2018-10-11 |
Silence Therapeutics Gmbh |
Ligand modified double-stranded nucleic acids
|
EP3385272A1
(en)
|
2017-04-05 |
2018-10-10 |
Silence Therapeutics GmbH |
Further novel oligonucleotide-ligand conjugates
|
AU2018265274B2
(en)
|
2017-05-11 |
2021-10-07 |
Gen-Probe Incorporated |
Compositions and methods for isolating target nucleic acids
|
WO2018226798A1
(en)
|
2017-06-07 |
2018-12-13 |
Gen-Probe Incorporated |
Detecting babesia species nucleic acid in a sample
|
CA3155871A1
(en)
|
2017-07-10 |
2019-01-17 |
Gen-Probe Incorporated |
Analytical systems and methods for nucleic acid amplification using sample assigning parameters
|
CA3072452A1
(en)
|
2017-08-11 |
2019-02-14 |
Gen-Probe Incorporated |
Compositions and methods for detecting staphylococcus aureus
|
EP3668984A4
(en)
|
2017-08-18 |
2021-09-08 |
Ionis Pharmaceuticals, Inc. |
MODULATION OF THE NOTCH SIGNALING PATH FOR THE TREATMENT OF RESPIRATORY DISORDERS
|
WO2019051173A1
(en)
|
2017-09-08 |
2019-03-14 |
Ionis Pharmaceuticals, Inc. |
MODULATORS OF SMAD7 EXPRESSION
|
BR112020005287A2
(pt)
|
2017-09-29 |
2020-09-24 |
Intellia Therapeutics, Inc. |
composições e métodos para edição de gene ttr e tratar amiloidose attr
|
EP3687581A1
(en)
|
2017-09-29 |
2020-08-05 |
Intellia Therapeutics, Inc. |
Polynucleotides, compositions, and methods for genome editing
|
JP2021512044A
(ja)
|
2017-11-02 |
2021-05-13 |
ヤンセン バイオファーマ インク. |
オリゴヌクレオチドコンストラクト及びその使用
|
CN111566212A
(zh)
|
2017-11-03 |
2020-08-21 |
因特尔纳技术有限公司 |
miRNA分子,等同物,安塔够妙或其来源用于治疗和/或诊断与神经元缺陷相关的病症和/或疾病或用于神经元生成和/或再生
|
TWI809004B
(zh)
|
2017-11-09 |
2023-07-21 |
美商Ionis製藥公司 |
用於降低snca表現之化合物及方法
|
US11377688B2
(en)
|
2017-11-17 |
2022-07-05 |
Gen-Probe Incorporated |
Compositions and methods for detecting C1orf43 nucleic acid
|
WO2019118550A1
(en)
|
2017-12-13 |
2019-06-20 |
Gen-Probe Incorporated |
Methods for biological sample processing
|
JP2021506274A
(ja)
|
2017-12-15 |
2021-02-22 |
ジェン−プローブ・インコーポレーテッド |
毒素産生Clostridium difficileを検出するための組成物および方法
|
WO2019126641A2
(en)
|
2017-12-21 |
2019-06-27 |
Ionis Pharmaceuticals, Inc. |
Modulation of frataxin expression
|
TW201934129A
(zh)
|
2018-01-15 |
2019-09-01 |
美商Ionis製藥公司 |
Dnm2表現之調節劑
|
WO2019147743A1
(en)
|
2018-01-26 |
2019-08-01 |
Massachusetts Institute Of Technology |
Structure-guided chemical modification of guide rna and its applications
|
AU2019212931A1
(en)
|
2018-01-29 |
2020-08-27 |
Gen-Probe Incorporated |
Analytical systems and methods
|
AU2019218557A1
(en)
|
2018-02-12 |
2020-08-20 |
Interna Technologies B.V. |
Anticancer microRNA and lipid formulations thereof
|
TW202000199A
(zh)
|
2018-03-02 |
2020-01-01 |
美商Ionis製藥公司 |
Irf4 表現之調節劑
|
EP3759127A4
(en)
|
2018-03-02 |
2022-03-30 |
Ionis Pharmaceuticals, Inc. |
COMPOUNDS AND METHODS FOR MODULATING AMYLOID BETA PRECURSOR PROTEIN
|
US11661601B2
(en)
|
2018-03-22 |
2023-05-30 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating FMR1 expression
|
EP3549610A1
(en)
|
2018-04-05 |
2019-10-09 |
Silence Therapeutics GmbH |
Nucleic acid conjugates
|
CA3094020A1
(en)
|
2018-04-11 |
2019-10-17 |
Ionis Pharmaceuticals, Inc. |
Modulators of ezh2 expression
|
CA3098144A1
(en)
|
2018-05-09 |
2019-11-14 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing atxn3 expression
|
SG11202010012PA
(en)
|
2018-05-09 |
2020-11-27 |
Ionis Pharmaceuticals Inc |
Compounds and methods for reducing fxi expression
|
CH716454B1
(de)
|
2018-06-13 |
2023-05-15 |
Gen Probe Inc |
Zusammensetzungen und Verfahren zum Nachweis der Nukleinsäure von Gruppe-B-Streptococcus.
|
CA3103429A1
(en)
|
2018-06-14 |
2019-12-19 |
Don W. Cleveland |
Compounds and methods for increasing stmn2 expression
|
MX2020013653A
(es)
|
2018-06-27 |
2021-03-02 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para la reduccion de la expresion de lrrk2.
|
CA3105684A1
(en)
|
2018-07-10 |
2020-01-16 |
Gen-Probe Incorporated |
Methods and systems for detecting and quantifying nucleic acids
|
TW202020154A
(zh)
|
2018-07-25 |
2020-06-01 |
美商Ionis製藥公司 |
用於減少atxn2表現之化合物及方法
|
JP2021531804A
(ja)
|
2018-07-31 |
2021-11-25 |
インテリア セラピューティクス,インコーポレイテッド |
原発性高シュウ酸尿症1型(ph1)を治療するためのヒドロキシ酸オキシダーゼ1(hao1)遺伝子編集のための組成物および方法
|
EP3830302B1
(en)
|
2018-08-01 |
2022-10-05 |
Gen-Probe Incorporated |
Compositions and methods for detecting nucleic acids of epstein-barr virus
|
JP2021532808A
(ja)
|
2018-08-08 |
2021-12-02 |
ジェン−プローブ・インコーポレーテッド |
Mycoplasma genitaliumを検出するための組成物、方法、およびキット
|
JP2021534101A
(ja)
|
2018-08-09 |
2021-12-09 |
ヴェルソー セラピューティクス, インコーポレイテッド |
Ccr2及びcsf1rを標的とするためのオリゴヌクレオチド組成物ならびにその使用
|
AU2019326462A1
(en)
|
2018-08-21 |
2021-03-25 |
Gen-Probe Incorporated |
Compositions and methods for amplifying, detecting or quantifying human cytomegalovirus
|
CA3108906A1
(en)
|
2018-08-24 |
2020-02-27 |
Gen-Probe Incorporated |
Compositions and methods for detecting bacterial nucleic acid and diagnosing bacterial vaginosis
|
WO2020069085A2
(en)
|
2018-09-27 |
2020-04-02 |
Gen-Probe Incorporated |
Compositions and methods for detecting bordetella pertussis and bordetella parapertussis nucleic acid
|
KR20210086621A
(ko)
|
2018-09-28 |
2021-07-08 |
인텔리아 테라퓨틱스, 인크. |
락테이트 데히드로게나제 (ldha) 유전자 편집을 위한 조성물 및 방법
|
WO2020081613A1
(en)
|
2018-10-16 |
2020-04-23 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunotherapy
|
CA3116918A1
(en)
|
2018-10-18 |
2020-04-23 |
Intellia Therapeutics, Inc. |
Compositions and methods for transgene expression from an albumin locus
|
JP2022512726A
(ja)
|
2018-10-18 |
2022-02-07 |
インテリア セラピューティクス,インコーポレーテッド |
核酸構築物及び使用方法
|
SG11202103735TA
(en)
|
2018-10-18 |
2021-05-28 |
Intellia Therapeutics Inc |
Compositions and methods for treating alpha-1 antitrypsin deficiencey
|
EP3867380A2
(en)
|
2018-10-18 |
2021-08-25 |
Intellia Therapeutics, Inc. |
Compositions and methods for expressing factor ix
|
WO2020086546A1
(en)
|
2018-10-22 |
2020-04-30 |
Gen-Probe Incorporated |
Compositions and methods for amplifying, detecting or quantifying human polyomavirus bk virus
|
TW202028222A
(zh)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Foxp3表現之調節劑
|
US11208650B2
(en)
|
2018-11-15 |
2021-12-28 |
Ionis Pharmaceuticals, Inc. |
Modulators of IRF5 expression
|
TW202030333A
(zh)
|
2018-12-20 |
2020-08-16 |
美商簡 探針公司 |
用於檢測瘧原蟲物種核酸之組成物及方法
|
SG11202107399WA
(en)
|
2019-01-31 |
2021-08-30 |
Ionis Pharmaceuticals Inc |
Modulators of yap1 expression
|
US11279932B2
(en)
|
2019-02-27 |
2022-03-22 |
Ionis Pharmaceuticals, Inc. |
Modulators of MALAT1 expression
|
US20220098647A1
(en)
|
2019-03-22 |
2022-03-31 |
Gen-Probe Incorporated |
Compositions and Methods for Detecting Group A Streptococcus
|
EP3946285A1
(en)
|
2019-03-28 |
2022-02-09 |
Intellia Therapeutics, Inc. |
Compositions and methods for ttr gene editing and treating attr amyloidosis comprising a corticosteroid or use thereof
|
WO2020198641A2
(en)
|
2019-03-28 |
2020-10-01 |
Intellia Therapeutics, Inc. |
Polynucleotides, compositions, and methods for polypeptide expression
|
EP3946598A1
(en)
|
2019-03-28 |
2022-02-09 |
Intellia Therapeutics, Inc. |
Compositions and methods comprising a ttr guide rna and a polynucleotide encoding an rna-guided dna binding agent
|
SG11202110679YA
(en)
|
2019-03-29 |
2021-10-28 |
Ionis Pharmaceuticals Inc |
Compounds and methods for modulating ube3a-ats
|
CA3176699A1
(en)
|
2019-05-03 |
2020-11-12 |
Gen-Probe Incorporated |
Receptacle transport system for an analytical system
|
CN114096683A
(zh)
|
2019-07-03 |
2022-02-25 |
简·探针公司 |
用于确定样品中阴道毛滴虫的存在的寡核苷酸
|
EP3956450A4
(en)
|
2019-07-26 |
2022-11-16 |
Ionis Pharmaceuticals, Inc. |
COMPOUNDS AND METHODS FOR MODULATION OF GFAP
|
CN114555621A
(zh)
|
2019-08-15 |
2022-05-27 |
Ionis制药公司 |
键修饰的寡聚化合物及其用途
|
US20220298548A1
(en)
|
2019-08-23 |
2022-09-22 |
Gen-Probe Incorporated |
Compositions, methods and kits for detecting treponema pallidum
|
TW202118873A
(zh)
|
2019-08-27 |
2021-05-16 |
美商維泰克斯製藥公司 |
用於治療與重複性dna有關之病症之組合物及方法
|
US20220333162A1
(en)
|
2019-09-05 |
2022-10-20 |
Gen-Probe Incorporated |
Detection of chlamydia trachomatis nucleic acid variants
|
US20220396786A1
(en)
|
2019-11-14 |
2022-12-15 |
Gen-Probe Incorporated |
Compositions and Methods for Capturing Target Nucleic Acids
|
SG10201914033YA
(en)
|
2019-12-31 |
2021-07-29 |
Wilmar International Ltd |
Polypeptides with Lipase Activity and Uses Thereof
|
EP4342999A3
(en)
|
2020-01-16 |
2024-04-24 |
DNAe Diagnostics Limited |
Compositions, kits and methods for isolating target polynucleotides
|
US20210239663A1
(en)
|
2020-01-31 |
2021-08-05 |
Regeneron Pharmaceuticals, Inc. |
Use of liquid chromatography and mass spectrometry to characterize oligonucleotides
|
US20220064638A1
(en)
|
2020-02-28 |
2022-03-03 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating smn2
|
EP4143304A2
(en)
|
2020-04-28 |
2023-03-08 |
Intellia Therapeutics, Inc. |
Methods of in vitro cell delivery
|
CA3181546A1
(en)
|
2020-05-01 |
2021-11-04 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating atxn1
|
WO2021224873A1
(en)
|
2020-05-07 |
2021-11-11 |
Grifols Diagnostic Solutions Inc. |
Methods and compositions for detecting sars-cov-2 nucleic acid
|
EP3922720A1
(en)
|
2020-06-09 |
2021-12-15 |
Universidad de Murcia |
Therapy to prevent adverse cardiac remodeling following an acute myocardial infarction
|
MX2022016338A
(es)
|
2020-06-29 |
2023-01-24 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para modular la plp1.
|
JP2023534457A
(ja)
|
2020-07-17 |
2023-08-09 |
ジェン-プローブ・インコーポレーテッド |
マクロライド耐性Mycoplasma genitaliumの検出
|
WO2022034555A1
(en)
|
2020-08-13 |
2022-02-17 |
Janssen Biopharma, Inc. |
Polynucleotide constructs and uses thereof
|
TW202218686A
(zh)
|
2020-09-09 |
2022-05-16 |
美商維泰克斯製藥公司 |
用於治療杜興氏肌肉失養症(duchenne muscular dystrophy)之組合物及方法
|
US20230393163A1
(en)
|
2020-10-21 |
2023-12-07 |
Gen-Probe Incorporated |
Fluid container management system
|
WO2022098933A1
(en)
|
2020-11-06 |
2022-05-12 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of dm1 with slucas9 and sacas9
|
US11447521B2
(en)
|
2020-11-18 |
2022-09-20 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating angiotensinogen expression
|
IL303505A
(en)
|
2020-12-11 |
2023-08-01 |
Intellia Therapeutics Inc |
Preparations and methods for reducing MHC CLASS II in the cell
|
TW202237845A
(zh)
|
2020-12-11 |
2022-10-01 |
美商英特利亞醫療公司 |
用於涉及去胺作用之基因體編輯之多核苷酸、組合物及方法
|
AU2021409732A1
(en)
|
2020-12-23 |
2023-07-20 |
Intellia Therapeutics, Inc. |
Compositions and methods for reducing hla-a in a cell
|
EP4267723A1
(en)
|
2020-12-23 |
2023-11-01 |
Intellia Therapeutics, Inc. |
Compositions and methods for genetically modifying ciita in a cell
|
JP2024502036A
(ja)
|
2020-12-30 |
2024-01-17 |
インテリア セラピューティクス,インコーポレイテッド |
操作されたt細胞
|
EP4277658A1
(en)
|
2021-01-15 |
2023-11-22 |
Board of Regents, The University of Texas System |
A trans-complementation system for sars-cov-2
|
WO2022170193A2
(en)
|
2021-02-08 |
2022-08-11 |
Intellia Therapeutics, Inc. |
T-cell immunoglobulin and mucin domain 3 (tim3) compositions and methods for immunotherapy
|
WO2022170194A2
(en)
|
2021-02-08 |
2022-08-11 |
Intellia Therapeutics, Inc. |
Lymphocyte activation gene 3 (lag3) compositions and methods for immunotherapy
|
CN117098840A
(zh)
|
2021-02-08 |
2023-11-21 |
因特利亚治疗公司 |
用于免疫疗法的自然杀伤细胞受体2b4组合物和方法
|
WO2022182957A1
(en)
|
2021-02-26 |
2022-09-01 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of myotonic dystrophy type 1 with crispr/sacas9
|
WO2022182959A1
(en)
|
2021-02-26 |
2022-09-01 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of myotonic dystrophy type 1 with crispr/slucas9
|
JP2024510996A
(ja)
|
2021-03-15 |
2024-03-12 |
ジェン-プローブ・インコーポレーテッド |
生物学的サンプル処理のための組成物および方法
|
WO2022204476A1
(en)
|
2021-03-26 |
2022-09-29 |
The Board Of Regents Of The University Of Texas System |
Nucleotide editing to reframe dmd transcripts by base editing and prime editing
|
WO2022229851A1
(en)
|
2021-04-26 |
2022-11-03 |
Crispr Therapeutics Ag |
Compositions and methods for using slucas9 scaffold sequences
|
WO2022234519A1
(en)
|
2021-05-05 |
2022-11-10 |
Crispr Therapeutics Ag |
Compositions and methods for using sacas9 scaffold sequences
|
EP4355759A1
(en)
|
2021-06-18 |
2024-04-24 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing ifnar1 expression
|
WO2022271780A1
(en)
|
2021-06-22 |
2022-12-29 |
Intellia Therapeutics, Inc. |
Methods for in vivo editing of a liver gene
|
WO2023002203A1
(en)
|
2021-07-21 |
2023-01-26 |
Dnae Diagnostics Limited |
Method and system comprising a cartridge for sequencing target polynucleotides
|
GB202110479D0
(en)
|
2021-07-21 |
2021-09-01 |
Dnae Diagnostics Ltd |
Compositions, kits and methods for sequencing target polynucleotides
|
GB202110485D0
(en)
|
2021-07-21 |
2021-09-01 |
Dnae Diagnostics Ltd |
Compositions, kits and methods for sequencing target polynucleotides
|
WO2023010008A1
(en)
|
2021-07-27 |
2023-02-02 |
Gen-Probe Incorporated |
Compositions and methods for detecting gastrointestinal pathogens
|
WO2023018637A1
(en)
|
2021-08-09 |
2023-02-16 |
Vertex Pharmaceuticals Incorporated |
Gene editing of regulatory elements
|
WO2023028471A1
(en)
|
2021-08-24 |
2023-03-02 |
Intellia Therapeutics, Inc. |
Programmed cell death protein 1 (pd1) compositions and methods for cell-based therapy
|
WO2023039444A2
(en)
|
2021-09-08 |
2023-03-16 |
Vertex Pharmaceuticals Incorporated |
Precise excisions of portions of exon 51 for treatment of duchenne muscular dystrophy
|
US20230193406A1
(en)
|
2021-09-22 |
2023-06-22 |
Herbalife International Of America, Inc. |
Methods and compositions for processing botanical materials
|
WO2023081200A2
(en)
|
2021-11-03 |
2023-05-11 |
Intellia Therapeutics, Inc. |
Cd38 compositions and methods for immunotherapy
|
WO2023081689A2
(en)
|
2021-11-03 |
2023-05-11 |
Intellia Therapeutics, Inc. |
Polynucleotides, compositions, and methods for genome editing
|
TW202345911A
(zh)
|
2022-03-08 |
2023-12-01 |
美商維泰克斯製藥公司 |
用於治療杜興氏肌肉失養症(duchenne muscular dystrophy)之部分外顯子44、50及53之精確切除
|
WO2023172926A1
(en)
|
2022-03-08 |
2023-09-14 |
Vertex Pharmaceuticals Incorporated |
Precise excisions of portions of exons for treatment of duchenne muscular dystrophy
|
WO2023185697A2
(en)
|
2022-03-29 |
2023-10-05 |
Accuredit Therapeutics (Suzhou) Co., Ltd. |
Compositions and methods for treatment of transthyretin amyloidosis
|
WO2023205606A1
(en)
|
2022-04-18 |
2023-10-26 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for enhancing aav therapy and decreasing tropism of aav to the liver
|
WO2023205148A1
(en)
|
2022-04-19 |
2023-10-26 |
Intellia Therapeutics, Inc. |
Chimeric antigen receptor compositions and uses
|
WO2023245108A2
(en)
|
2022-06-16 |
2023-12-21 |
Intellia Therapeutics, Inc. |
Compositions and methods for reducing mhc class i in a cell
|
WO2023245109A2
(en)
|
2022-06-16 |
2023-12-21 |
Intellia Therapeutics, Inc. |
Compositions and methods for genomic editing
|
WO2023245113A1
(en)
|
2022-06-16 |
2023-12-21 |
Intellia Therapeutics, Inc. |
Methods and compositions for genetically modifying a cell
|
WO2024006955A1
(en)
|
2022-06-29 |
2024-01-04 |
Intellia Therapeutics, Inc. |
Engineered t cells
|
WO2024020352A1
(en)
|
2022-07-18 |
2024-01-25 |
Vertex Pharmaceuticals Incorporated |
Tandem guide rnas (tg-rnas) and their use in genome editing
|
EP4311579A1
(en)
|
2022-07-29 |
2024-01-31 |
Association Française contre les Myopathies |
B cell-specific mab-sirna conjugates improve myasthenia
|
WO2024026474A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
WO2024035952A1
(en)
|
2022-08-12 |
2024-02-15 |
Remix Therapeutics Inc. |
Methods and compositions for modulating splicing at alternative splice sites
|
WO2024054924A1
(en)
|
2022-09-08 |
2024-03-14 |
Gen-Probe Incorporated |
Method of detecting nucleic acid analytes using dual-specificity primers
|
WO2024061296A2
(en)
|
2022-09-22 |
2024-03-28 |
Accuredit Therapeutics (Suzhou) Co., Ltd. |
Compositions and methods for treatment of hypercholesterolemia and/or cardiovascular disease
|